...
首页> 外文期刊>European review for medical and pharmacological sciences. >MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2
【24h】

MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2

机译:miR-605-3p通过um-consemate ezh2抑制前列腺癌的恶性进展

获取原文
           

摘要

OBJECTIVE: This study aimed to investigate the effect of microRNA-605-3p (miR-605-3p) on cell proliferation, invasion and migration in prostate cancer cells, as well as its effects on the Enhancer Zeste Homolog 2 (EZH2) expression and the potential regulatory mechanisms. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was applied to detect the miR-605-3p expression in 52 pairs of Prostate Cancer (PCa) tissues and normal tissues, and to analyze the relationship between miR-605-3p expression and PCa pathological parameters. MiR-605-3p mimics were transfected into PCa cell line PC-3 and DU145 to achieve miR-605-3p overexpression. Then, Cell Counting Kit-8 (CCK-8), cell colony formation assay and transwell invasion and migration assay were performed to analyze miR-605-3p’s effect on the biological function of prostate cancer cells. Finally, the potential mechanisms of downstream genes were explored through bioinformatics analysis and recovery experiments. RESULTS: We found that miR-605-3p expression in PCa was markedly lower than that in normal tissues. Patients with low miR-605-3p expression had higher tumor stage, higher incidence of lymph node metastasis and distant metastasis. In vitro analysis showed that miR-605-3p overexpression leads to a significant decrease in cell proliferation, invasion and migration ability. Subsequently, it was verified in cell line and tissue that EZH2 expression was remarkably increased in PCa, which was negatively correlated with miR-605-3p expression. In addition, the recovery experiment found that EZH2 can counteract the role of miR-605-3p in PCa, together they affected the malignant progression of PCa. CONCLUSIONS: MiR-605-3p was significantly associated with PCa stage, lymph node metastasis and distant metastasis and the poor prognosis; besides, it can inhibit the malignant progression of PCa. In addition, the study showed that miR-605-3p may inhibit the proliferation, invasion and migration ability of PCa by regulating EZH2.
机译:目的:本研究旨在探讨MicroRNA-605-3P(miR-605-3p)对前列腺癌细胞中细胞增殖,侵袭和迁移的影响,以及其对增强子Zeste同源物2(EzH2)表达的影响潜在的监管机制。患者和方法:施用定量实时 - 聚合酶链反应(QRT-PCR)检测52对前列腺癌(PCA)组织和正常组织中的miR-605-3p表达,并分析miR-605之间的关系-3P表达和PCA病理参数。 MiR-605-3P模拟物被转染到PCA细胞系PC-3和DU145中,以实现MiR-605-3P过表达。然后,进行细胞计数试剂盒-8(CCK-8),细胞群形成测定和Transwell侵袭和迁移测定以分析miR-605-3p对前列腺癌细胞的生物学功能的影响。最后,通过生物信息学分析和恢复实验探讨了下游基因的潜在机制。结果:我们发现PCA中的miR-605-3p表达明显低于正常组织中的miR-605-3p表达。低miR-605-3P表达的患者具有较高的肿瘤阶段,淋巴结转移和远处转移的发病率较高。体外分析表明,miR-605-3p过表达导致细胞增殖,侵袭和迁移能力的显着降低。随后,在细胞系和组织中验证,PCA中的EZH2表达显着增加,与miR-605-3p表达呈负相关。此外,恢复实验发现,EZH2可以抵消MIR-605-3P在PCA中的作用,它们在一起影响了PCA的恶性进展。结论:miR-605-3p与PCA阶段,淋巴结转移和远处转移和预后差有关;此外,它可以抑制PCA的恶性进展。此外,该研究表明,MIR-605-3P可以通过调节EZH2来抑制PCA的增殖,侵袭和迁移能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号